Results 301 to 310 of about 406,491 (336)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

The Lancet, 2020
BACKGROUND Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer.
J. Cortés, D. Cescon, H. Rugo, Z. Nowecki, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, E. Holgado, H. Iwata, N. Masuda, M. Otero, E. Gokmen, S. Loi, Zifang Guo, Jingyi Zhao, G. Aktan, V. Karantza, P. Schmid   +19 more
semanticscholar   +1 more source

Immunotherapy in Triple-Negative Breast Cancer

The Cancer Journal, 2021
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A subset of TNBC is immune activated, suggesting that immunotherapy may be a viable treatment strategy. Phase III clinical trials have shown that atezolizumab or pembrolizumab is well-tolerated in combination with chemotherapy, with progression-free ...
openaire   +2 more sources

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

New England Journal of Medicine, 2019
BACKGROUND Standard chemotherapy is associated with low response rates and short progression‐free survival among patients with pretreated metastatic triple‐negative breast cancer.
Aditya Bardia, Íngrid A Mayer, Linda T Vahdat   +2 more
exaly   +2 more sources

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing

Cell, 2018
SUMMARY Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy. An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or alternatively through the ...
Charissa Kim, Ruli Gao, Emi Sei
exaly   +2 more sources

An overview of triple-negative breast cancer

Archives of Gynecology and Obstetrics, 2015
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast cancers simply defined by the absence of estrogen receptor, progesterone receptor and overexpression of human epidermal growth factor receptor 2 gene.
Pankaj Kumar, Rupali Aggarwal
openaire   +2 more sources

Metastatic Triple-negative Breast Cancer

Clinical Oncology, 2011
The triple-negative class (oestrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) comprises about 15% of breast cancer. It is associated with a poor prognosis compared with tumours that are positive for hormone receptors or HER2.
E A, Rakha, S, Chan
openaire   +2 more sources

Pathology of triple negative breast cancer

Seminars in Cancer Biology, 2021
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression and HER2 gene amplification and represents 24 % of newly diagnosed breast neoplasms. In this review, pathological aspects of triple-negative breast cancer are illustrated, with particular attention to the seminal studies that defined this subtype of ...
Filippo, Borri, Annarita, Granaglia
openaire   +2 more sources

Epidemiology of triple negative breast cancers [PDF]

Breast Disease, 2011
Triple negative (TN) breast cancers fail to express the three most common breast cancer receptors; i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Accumulating data demonstrate that epidemiological risk factor profiles also vary between TN (ER-PR-HER2-) and other breast cancers, especially ...
Gretchen L, Gierach, Aileen, Burke, William F, Anderson   +2 more
openaire   +2 more sources

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

New England Journal of Medicine
BACKGROUND In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing ...
P. Schmid, J. Cortés, R. Dent, H. McArthur, L. Pusztai, S. Kümmel, C. Denkert, Y. Park, R. Hui, N. Harbeck, M. Takahashi, Seock-Ah Im, M. Untch, P. Fasching, M. Mouret-Reynier, T. Foukakis, M. Ferreira, F. Cardoso, Xuan Zhou, V. Karantza, K. Tryfonidis, G. Aktan, J. O’Shaughnessy   +22 more
semanticscholar   +1 more source

Pharmacotherapy of triple-negative breast cancer

Expert Opinion on Pharmacotherapy, 2009
The term 'triple-negative breast cancer' defines tumors that do not express estrogen receptors, progesterone receptors or Her2 on immunohistochemical analysis. This subgroup accounts for 15% of all types of breast cancer. Histologically, triple-negative breast cancers are poorly differentiated and are characterized by an aggressive clinical history.
Cagatay, Arslan, Omer, Dizdar, Kadri, Altundag   +2 more
openaire   +2 more sources